ResistancePlus^® MG

Enabling Resistance Guided Therapy

Detect Mycoplasma genitalium and macrolide resistance markers MgPa for M. genitalium detection, plus four 23S rRNA mutations (A2058T, A2058C, A2058G, A2059G) in a single-well multiplex qPCR test.

Why use ResistancePlus® MG?

Resistance to the macrolide treatment (Azithromycin) is of growing concern when managing M. genitalium (Mgen) infections. Guidelines around the world now call for the practice of Resistance Guided Therapy to guide appropriate treatment decisions, reduce potential for spreading infection among vulnerable populations, and support antibiotic stewardship.

• Resistance Guided Therapy is clinically demonstrated to improve patient cure rate and overall patient management.

• Detection of macrolide resistance can reduce time to cure, preventing ongoing transmission.

Tested on thousands of clinical samples, ResistancePlus^® MG demonstrates excellent sensitivity and specificity.

ResistancePlus® MG workflow solution

Streamline your workflow and increase productivity for rapid, routine diagnostics. Full automation options include sample and qPCR set-up, through to validated software solutions for automated result calling and simple data processing.

• Validated on a range of specimen types and sample collection devices

• Validated on a range of sample extraction and qPCR platforms

SpeeDx analysis software is included in contract pricing, is license free, and installed on a high security and GDPR compliant platform. Designed to support the IVD laboratory environment, features include:

• audit trails

• user traceability

• LIS connectivity

• QA and batch management

Increase capacity of your existing qPCR instrumentation through universal run conditions compatible with all ResistancePlus^® products.

ResistancePlus® MG Performance Specifications

Demonstrated clinical performance – for more detail please see the ResistancePlus^® MG Instructions for Use.